Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Sells $336,929.84 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Rong Zhou sold 6,893 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $48.88, for a total transaction of $336,929.84. Following the completion of the sale, the executive vice president now directly owns 118,388 shares in the company, valued at $5,786,805.44. This represents a 5.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Rong Zhou also recently made the following trade(s):

• On Monday, August 26th, Rong Zhou sold 4,000 shares of Amphastar Pharmaceuticals stock. The shares were sold at an average price of $48.35, for a total transaction of $193,400.00.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH opened at $44.61 on Friday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $36.56 and a twelve month high of $65.92. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The company has a 50-day moving average of $48.40 and a 200-day moving average of $44.37. The firm has a market cap of $2.14 billion, a price-to-earnings ratio of 14.87, a price-to-earnings-growth ratio of 0.88 and a beta of 0.82.

Analyst Ratings Changes

A number of analysts have weighed in on AMPH shares. StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Finally, Piper Sandler decreased their target price on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $63.00.

Institutional Trading of Amphastar Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Aurora Investment Counsel lifted its stake in Amphastar Pharmaceuticals by 0.4% during the third quarter. Aurora Investment Counsel now owns 54,698 shares of the company’s stock valued at $2,654,000 after buying an additional 232 shares in the last quarter. GAMMA Investing LLC lifted its stake in Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after buying an additional 273 shares in the last quarter. Crossmark Global Holdings Inc. lifted its position in shares of Amphastar Pharmaceuticals by 2.5% in the second quarter. Crossmark Global Holdings Inc. now owns 11,300 shares of the company’s stock worth $452,000 after purchasing an additional 275 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after purchasing an additional 301 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in shares of Amphastar Pharmaceuticals by 23.9% in the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after purchasing an additional 309 shares in the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.